



MEDICO REMEDIES LTD.

A WHO-GMP, ISO 9001-2015 & GOVT. RECOGNISED STAR EXPORT HOUSE

Manufacturers of Pharmaceutical Formulations



CIN : L24230MH1994PLC077187
GSTIN- 27AABCM8349L1ZY.

Regd. Office : 1105/1106, Hubtown Solaris, N. S. Phadke Marg, Opp. Teligali, Andheri - East, Mumbai - 400 069. • Tel. : +91-22-2682 1054 / 1055 / 2683 7116
Email : medicoremedies@yahoo.com • info@medicoremedies.com • Website : www.medicoremediesindia.com • www.medicoremediesindia.net • www.tabletandcapsules.com

Date: 12th February 2026

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400001 Scrip Code: 540937	National Stock Exchange of India Limited 5 th Floor, Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai-400051 Symbol: MEDICO
---	--

Dear Sir/Madam,

Re.: Outcome of Board Meeting held today

Sub: Intimation under Regulation 30 (read with Part A of Schedule III) (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of our Company at their meeting held today i.e. 12th February 2026 has, inter alia considered and approved the following:

1. Unaudited Standalone Financial Results for the quarter and half year ended 31st December 2025 along with Auditors' Limited Review Report thereon; (enclosed)

We wish to inform you that the Board Meeting commenced today at 5:00 P.M. and concluded at 05:30 P.M.

Kindly take the same on record.

Thanking you,

FOR MEDICO REMEDIES LIMITED

HARESH MEHTA
CHAIRMAN & WHOLE-TIME DIRECTOR
DIN: 01080289

Encl: As above



Independent Auditor's Limited Review Report on Quarterly Unaudited Standalone Financial Results of Medico Remedies Limited pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015, as amended

To

THE BOARD OF DIRECTORS

MEDICO REMEDIES LIMITED

1105/1106, 11th Floor, Hubtown Solaris

Opp. Telli Galli, N S Phadke Marg,

Andheri East, Mumbai - 400069

Dear Sirs,

Re: Limited Review Report of the Unaudited Standalone Financial Results for the quarter and period ended 31st December, 2025

We have reviewed the accompanying Statement of unaudited Standalone Financial Results of Medico Remedies Limited ("the Company") for the quarter and nine months ended 31st December, 2025, together with the notes thereon, ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015 ('the Regulation') as amended (the "Listing Regulations").

This Statement which is the responsibility of the Company's Management has been reviewed by Audit Committee and approved by the Board of Directors at their respective meetings held on 12th February, 2026 has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (IND AS 34), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the company personnel and analytical procedure applied to financial data and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.





Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Standalone Financial Results prepared in accordance with applicable Indian Accounting Standard specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting principles and policies has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matters

We have reviewed the financial results for quarter ended 31st December 2025 and financial position as on that date. The review/audit for the period from 1st April 2025 to 30th June 2025 and for the previous financial year i.e. FY 2024-25 was done by the previous auditor (M/s V J Shah & Co) of the Company. We have not performed any procedures for those periods, and our report is not modified in respect of those matters.

For Shah Shroff & Associates**Chartered Accountants****Firm Registration No.: 128920W****Yashesh Shroff**
Partner**Membership Number – 103277****UDIN: 26103277RP45HM4036****Place: Mumbai****Date: 12.02.2026**


Medico Remedies Limited
(CIN - L24230MH1994PLC077187)
Statement of Unaudited Standalone Financial Results for the Period ended 31 December, 2025

(Rs. In lakhs)

Sr. No.	Particulars	Quarter Ended			For the Period Ended		Year Ended
		31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income from Operations						
	(a) Revenue from operations	5,868.29	5,263.52	3,948.99	14,956.96	10,963.74	15,094.06
	(b) Other Income	67.68	172.48	142.50	305.97	239.64	268.94
	Total Income	5,935.97	5,436.00	4,091.49	15,262.93	11,203.38	15,363.00
2	Expenses						
	(a) Cost of materials consumed	3,618.44	4,334.92	3,092.90	10,824.28	8,197.38	11,139.04
	(b) Purchase of stock-in-trade	221.47	111.79	33.39	395.73	153.83	209.69
	(c) Changes in inventories of finished goods, work-in-progress and stock- in trade	570.91	(402.28)	(260.14)	(30.88)	(254.69)	(515.77)
	(d) Employee benefits expense	212.92	181.00	187.58	564.27	469.50	627.65
	(e) Finance Cost	38.63	23.51	27.62	90.24	66.45	115.85
	(f) Depreciation and amortisation expense	79.02	73.36	76.41	229.28	226.45	303.01
	(g) Other expenses	811.35	766.28	583.95	2,215.96	1,563.94	2,133.16
	Total Expenses	5,552.74	5,088.59	3,741.70	14,288.89	10,422.86	14,012.63
3	Profit before Exceptional Items & Tax (1-2)	383.23	347.41	349.79	974.04	780.52	1,350.37
4	Add/(Less) : Exceptional Item	-	-	-	-	-	-
5	Profit before tax (3+4)	383.23	347.41	349.79	974.04	780.52	1,350.37
6	Tax Expense :						
	- Current Tax	86.00	77.42	79.14	217.00	192.54	381.00
	- Deferred Tax	10.00	13.17	8.68	31.18	12.74	(39.19)
	- short/(Excess) Provision of Previous Years	-	-	-	-	-	(0.76)
	Total Tax Expenses	96.00	90.59	87.82	248.18	205.28	341.05
7	Net Profit for the period after tax (5-6)	287.23	256.82	261.97	725.86	575.24	1,009.32
8	Other Comprehensive Income / (Loss)						
	Items that will not be reclassified to Profit & Loss in subsequent periods						
	(i) Remeasurement of defined benefit plan	0.16	0.16	0.30	0.48	0.90	0.63
	(ii) Income tax related to items no (i) above	(0.04)	(0.04)	(0.07)	(0.12)	(0.23)	(0.16)
	Other Comprehensive Income / (Loss) (net of tax)	0.12	0.12	0.23	0.36	0.67	0.47
9	Total Comprehensive Income for the period (net of tax) (7+8)	287.35	256.94	262.19	726.22	575.91	1,009.79
10	Paid-up Equity Share Capital (Face Value ₹ 2/- per share)	1,659.68	1,659.68	1,659.68	1,659.68	1,659.68	1,659.68
11	Other Equity	-	-	-	-	-	4,587.21
12	EPS ₹ - (Not Annualised)						
	- Basic	0.35	0.31	0.32	0.87	0.69	1.22
	- Diluted	0.35	0.31	0.32	0.87	0.69	1.22

For Medico Remedies Limited

Rishit Mehta
Whole Time Director
DIN: 07121224



For Medico Remedies Limited

Harshit Mehta
Managing Director
DIN: 05144280


Notes:

1. The above unaudited standalone financial results of the company were reviewed and recommended by the audit committee on February 12, 2026 and subsequently approved by the Board of Directors at its meeting held on February 12, 2026. The review report has been filed with stock exchange and is available on the Company's website.
2. The figures for the quarter ended on 31st December 2025 are balancing figures between the reviewed figures for the quarter ended 30th September 2025 and reviewed year to date figures upto nine months ended 31st December 2025.
3. The standalone financial results for the quarter ended on 31st December, 2025 have been subjected to Limited Review by statutory auditors of the company and the statutory auditors have issued unmodified report on unaudited financial results.
4. The above financial results have been prepared as per IND AS and all standards and requirements of IND AS are complied with by the company.
5. Medico Remedies Limited is a pharmaceutical formulation manufacturing company and the management reviews the performance of the company as a single operating segment in accordance with IND-AS 108 "Operating Segments" notified pursuant to Companies (Accounting Standard) Rules, 2015. Accordingly, no segment information/segment reporting has been furnished within. Details of geographical segments are disclosed below:

PARTICULARS		QE 31.12.2025	QE 30.09.2025
		Amount (Rs. In Lakh)	Amount (Rs. In Lakh)
1)	Sales of products within India	689.73	542.92
2)	Sales of products Outside India	5156.033	4675.40
	Sub- Total	5845.77	5218.32

6. Previous periods figures have been regrouped / reclassified where required to make them compatible with the figures of current periods.
7. The company does not have any subsidiary/associate/joint venture company as on 31st December 2025.
8. The result for the quarter ended December 31, 2025 is available on the BSE Limited website (URL: www.bseindia.com), NSE Limited website (URL: www.nseindia.com) and on the Company's website (URL: www.medicoremedies.com)

For and on behalf of the board,
For Medico Remedies Limited


Rishit Mehta
Whole Time Director
DIN: 07121224
Place: Mumbai
Date: February 12, 2026




Harshit Mehta
Managing Director
DIN:05144280
Place: Mumbai
Date: February 12, 2026